AbbVie Inc. (ABBV) stock — is it a good business?

AbbVie Inc. (ABBV) stock — is it a good business? — InspectStocks

Just reported

Q3 2026 results

From AbbVie's results release of October 30, 2026; its quarterly report has since been filed.

Revenue
Actual
$17.4B
+10% y/y
+2.4% q/q
Guided
—
No guide given
EPS, GAAP
Actual
$2.37
+17% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
$6.27B
+229% y/y
-2.6% q/q
Guided
—
No guide given

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

The full earnings report →

How it makes money

Sales of medicines and therapies100%

Shares of revenue are estimates for fiscal year 2025, high confidence, not figures from a filing.

Competes with

What it sells6

Skyrizi
An injectable biologic medicine for autoimmune diseases including psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis. In 2026, U.S. and European regulators also approved it for some children with plaque psoriasis.
Rinvoq
A once-daily pill for several inflammatory and autoimmune diseases, including rheumatoid arthritis, atopic dermatitis, ulcerative colitis and Crohn's disease. European regulators approved it for vitiligo and severe alopecia areata in 2026.
Humira
An injectable biologic medicine used for autoimmune conditions including rheumatoid arthritis, psoriasis, Crohn's disease and ulcerative colitis. It faces competition from biosimilar medicines.

Show 3 more

Botox Therapeutic and Botox Cosmetic
An injectable medicine used therapeutically for conditions including chronic migraine and muscle disorders; its cosmetic version temporarily reduces the appearance of facial lines.
Vraylar
A prescription medicine used to treat schizophrenia and episodes of bipolar disorder, and alongside other medicine for major depression.
Venclexta
A cancer medicine used for blood cancers including chronic lymphocytic leukemia and acute myeloid leukemia. In 2026, U.S. regulators approved a combination with another cancer medicine for some previously untreated adults with chronic lymphocytic leukemia.

Who buys it5

Wholesalers and distributors buy medicines for resale to pharmacies, hospitals and other healthcare providers.
Government agencies and public health programs buy medicines or set coverage and reimbursement terms.
Health insurers and pharmacy benefit managers influence which medicines patients can access and the prices or rebates paid.

Show 2 more

Hospitals, health facilities, specialty pharmacies and independent pharmacies buy medicines for use or dispensing to patients.
Physicians and other licensed healthcare providers prescribe AbbVie's prescription medicines and can buy some aesthetic products and devices directly.

What it stands on, and what could break it

What the business leans on

1AbbVie relies on large wholesale distributors to move its medicines, especially in the United States.
2Some medicines or manufacturing components depend on a limited number of suppliers, and in some cases a single supply source.
3Revenue depends on patents and regulatory exclusivity; Humira already faces biosimilar competition.
4Pricing and patient access depend partly on government reimbursement rules, insurers and pharmacy benefit managers.
5The business depends on discovering, testing and obtaining regulatory approval for new medicines, including products developed with collaborators.

What could go wrong

1Patent expirations and biosimilar or generic competition can reduce sales. Humira's sales continued to fall amid biosimilar competition in the six months ended June 30, 2026.
2Government price controls, reimbursement limits and pressure from insurers and pharmacy benefit managers can reduce the prices AbbVie receives for its medicines.
3Research and development may not produce medicines that pass clinical trials and regulatory review or attract enough use after approval, leaving gaps as existing products lose exclusivity.

Full financial statements →

About AbbVie Inc.

AbbVie researches, tests, makes and sells prescription medicines and some medical devices. Its medicines treat immune diseases, neurological conditions, cancers, migraine, eye diseases and other conditions; it also sells cosmetic injections, fillers and skincare products. It sells mainly through wholesalers and distributors, with some aesthetic products sold directly to licensed health professionals.

Head office: North Chicago, Illinois, United States
Founded: 2012 (incorporated; began independent public trading in 2013)
Employees: Approximately 57,000 (December 31, 2025, high confidence)
Listed on: New York Stock Exchange
Financial year ends: December 31

Built from AbbVie Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.

Just reported

Q3 2026 results

From AbbVie's results release of October 30, 2026; its quarterly report has since been filed.

Revenue
Actual
$17.4B
+10% y/y
+2.4% q/q
Guided
—
No guide given
EPS, GAAP
Actual
$2.37
+17% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
$6.27B
+229% y/y
-2.6% q/q
Guided
—
No guide given

The full earnings report →

Keep exploring

The themes AbbVie is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Highest-graded in Drug Manufacturers General

Graded A or B and worth $2B or more: A first, then the largest.

All 19 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises